Clinical trials: Dialysis
Anemia
Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent
- Trial name
- NCT00704353
- Testing
- Ferric Carboxymaltose, Standard Medical Care (SMC)
- Where
- United States
- Volunteers
- 735 people
- Sponsor
- American Regent, Inc.
Chronic Renal Failure, Chronic Kidney Disease
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)
The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- NCT00453973
- Testing
- peginesatide
- Where
- 20 sites in Bulgaria, Poland and 2 more
- Volunteers
- 114 people
- Sponsor
- Affymax
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02378662
- Testing
- MDGN201 TARGTEPO
- Where
- 2 sites in Israel
- Volunteers
- 2 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Hyperkalaemia
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
Prescribing Sodium zirconium cyclosilicate (SZC) with enhanced nutritional advice to participants with hyperkalaemia on haemodialysis will reduce serum K+ (S-K+ ) and enable the consumption of more fruit and vegetables and more…
- Trial name
- GRAZE (NCT04997161)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Enhanced dietary advice, Standard dietary advice including K+ restriction.
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Anemia
A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis
This single arm study will assess the efficacy and safety of subcutaneous Mircera for correction of anemia in participants with chronic kidney disease who are not treated with erythropoiesis stimulating agent (ESA) and not on…
- Trial name
- MERCUR (NCT00559637)
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 50 sites in Germany
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Replacement Therapy, Renal
Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)
In a prospective, non-interventional, monocentric observational study the pharmacokinetic properties of selected antiinfective drugs during sustained low-efficiency dialysis (SLED) will be analyzed.
- Trial name
- PhA-SLED (NCT02287493)
- Testing
- Pharmacokinetic Analysis
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in PD US Trial
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02468414
- Testing
- MDGN201 TARGTEPO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Anaemia
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
This Phase 3 study in hemodialysis-dependent subjects with anemia will evaluate the efficacy and safety of daprodustat administered three-times weekly compared to epoetin alfa, the current standard of care.
- Trial name
- NCT03400033
- Testing
- Daprodustat tablets, Epoetin alfa vials, Saline vials or bags
- Where
- 91 sites in United States, Argentina and 11 more
- Volunteers
- 407 people
- Sponsor
- GlaxoSmithKline
Fluid Loss, Dialysis
Clinical Evaluation of the CM-1500 During Hemodialysis
The study is a prospective, single-arm, non-randomized, non-blinded, non-controlled, non-significant risk, single center study enrolling up to 20 subjects consented to undergo a hemodialysis session as a part of their standard…
- Trial name
- NCT05125848
- Testing
- CM-1500
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Zynex Monitoring Solutions
Anemia
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.
- Trial name
- NCT02174731
- Testing
- Roxadustat, Epoetin alfa
- Where
- 188 sites in United States, Australia and 16 more
- Volunteers
- 2,133 people
- Sponsor
- AstraZeneca
Hemodialysis Complication, Hypotension of Hemodialysis
Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease
Bradykinin is a potent vasodilator that is formed by the activation of the kallikrein-kinin system. We and others have shown that bradykinin increased during hemodialysis; however, the role of bradykinin in dialysis-induced…
- Trial name
- Hinder (NCT05297786)
- Testing
- Lanadelumab Injection [Takhzyro]
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Vanderbilt University Medical Center
Anemia of Chronic Kidney Disease
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period ("Randomized Period"), followed by an 8-week open-label safety extension period, where all subjects…
- Trial name
- NCT02268994
- Testing
- ferric citrate
- Where
- 36 sites in United States
- Volunteers
- 234 people
- Sponsor
- Keryx Biopharmaceuticals
Chronic Kidney Disease, Secondary Hyperparathyroidism
20070360 Incident Dialysis
Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis
- Trial name
- NCT00803712
- Testing
- Cinacalcet, Vitamin D
- Volunteers
- 313 people
- Sponsor
- Amgen
Peritoneal Dialysis (PD), Anemia
Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis
The main purpose is to determine the pharmacokinetic (PK) profile, maximum concentration (Cmax) and Area Under the Concentration Time Curve (AUC0-t) of Triferic iron administered intraperitoneally in patients with chronic kidney…
- Conditions
- Peritoneal Dialysis (PD), Anemia, Chronic Kidney Disease
- Trial name
- NCT02909153
- Testing
- Triferic
- Volunteers
- 30 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Anaemia, Aspergillosis, Allergic Bronchopulmonary
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
- Trial name
- NCT02879305
- Testing
- Daprodustat, rhEPO, Iron therapy
- Where
- 462 sites in United States, Argentina and 33 more
- Volunteers
- 2,964 people
- Sponsor
- GlaxoSmithKline
Kidney Failure, Chronic, Peritoneal Dialysis-associated Peritonitis
Prevention of Peritonitis in Peritoneal Dialysis
BACKGROUND: Peritonitis remains a significant problem in peritoneal dialysis (PD). It is the leading cause of technique failure, and contributes to mortality. The incidence is highest during the first year of treatment.
- Conditions
- Kidney Failure, Chronic, Peritoneal Dialysis-associated Peritonitis, Dialysis Capd Infection
- Trial name
- PEPS (NCT01293799)
- Testing
- Retraining
- Where
- Sweden
- Volunteers
- 713 people
- Sponsor
- Sahlgrenska University Hospital
Kidney Failure, Chronic
Deprescribing for Older Dialysis Patients
Aim 1 of the study is to identify the elements of a deprescribing intervention that address contextual factors specific to dialysis.
- Trial name
- NCT03631290
- Testing
- Deprescribing Intervention
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Uremic Pruritus
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session.
- Trial name
- NCT03422653
- Testing
- CR845 0.5 mcg/kg
- Where
- 57 sites in United States
- Volunteers
- 378 people
- Sponsor
- Cara Therapeutics, Inc.
Dialysis, Anemia
Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment
The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.
- Trial name
- NCT01414075
- Testing
- Roxadustat, Oral Iron, IV Iron
- Where
- 7 sites in United States, Hong Kong and 2 more
- Volunteers
- 60 people
- Sponsor
- Kyntra Bio
Kidney Failure, Chronic
Advance Care Planning With Older Patients Who Have End-stage Kidney Disease
This study will test the feasibility of carrying out a randomised controlled trial, incorporating a mixed methods process evaluation, to evaluate advance care planning with older patients who have end-stage kidney disease.
- Trial name
- ACREDiT (NCT02631200)
- Testing
- Advance care plan
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Queen's University, Belfast